Six Country Vignettes: Strengthening Radiotherapy and Theranostics.

Brachytherapy Global health Low-middle-income countries Nuclear medicine Public health Radiotherapy Theranostics

Journal

Journal of cancer policy
ISSN: 2213-5383
Titre abrégé: J Cancer Policy
Pays: England
ID NLM: 101639933

Informations de publication

Date de publication:
29 Mar 2024
Historique:
received: 29 11 2023
revised: 11 03 2024
accepted: 16 03 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 31 3 2024
Statut: aheadofprint

Résumé

For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in de novo establishment or improvement of RT and theranostics infrastructure. The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein. Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69-38.00 ROs, 1.00-26.00 NMPs, and 0.30-3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications. Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches. Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully. Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions.

Sections du résumé

BACKGROUND BACKGROUND
For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in de novo establishment or improvement of RT and theranostics infrastructure.
METHODS METHODS
The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein.
RESULTS RESULTS
Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69-38.00 ROs, 1.00-26.00 NMPs, and 0.30-3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications.
CONCLUSION CONCLUSIONS
Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches. Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully.
POLICY SUMMARY UNASSIGNED
Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions.

Identifiants

pubmed: 38556128
pii: S2213-5383(24)00005-5
doi: 10.1016/j.jcpo.2024.100471
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100471

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest none

Auteurs

Miriam Mikhail-Lette (M)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria. Electronic address: M.Mikhail-Lette@iaea.org.

Lisbeth Cordero (L)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Yolande Lievens (Y)

Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.

Akram Al-Ibraheem (A)

Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.

Jean-Luc Urbain (JL)

Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Bhishamjit Chera (B)

Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.

Kristoff Muylle (K)

Department of Nuclear Medicine, AZ Delta, Roselare, Belgium.

Aude Vaandering (A)

Department of Radiation Oncology, Université Catholique de Louvain, Saint-Luc University Hospital, Brussels, Belgium.

Arthur Accioly Rosa (AA)

Department of Radiation Oncology, Oncoclínicas Salvador and Hospital Santa Izabel, Salvador, Bahia, Brazil.

Juliano Julio Cerci (JJ)

Department of Nuclear Medicine, Quanta Diagnóstico e Terapia, Curitiba, Brazil.

Mike Sathekge (M)

Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.

Minjmaa Minjgee (M)

National Cancer Center, Ulaanbaatar, Mongolia.

Erdenekhuu Nansalmaa (E)

National Cancer Center, Ulaanbaatar, Mongolia.

Sereegotov Erdenechimeg (S)

First State Central Clinic, National Medical University of Mongolia, Ulaanbaatar, Mongolia.

Rolando Loría Ruíz (RL)

Radiation Therapy Center Siglo 21, San Jose, Costa Rica; Hospital México and Clínica Bíblica, Caja Costarricense de Seguro Social, San Jose, Costa Rica.

Andrew Scott (A)

Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.

Diana Paez (D)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Francesco Giammarile (F)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Anna Veduta (A)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Erika Minoshima (E)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Shrikant Vichare (S)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

May Abdel-Wahab (M)

International Atomic Energy Agency Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria.

Classifications MeSH